Skip to main content
Fig. 9 | BMC Medical Genomics

Fig. 9

From: A novel natural killer-related signature to effectively predict prognosis in hepatocellular carcinoma

Fig. 9

Application of risk score in immunotherapy, Chemotherapy and target therapy. A Prediction of immunotherapy response based on the TIDE algorithm. IPS score for immunotherapy. B CTLA4- PD1 − . C CTLA4 + PD1 − . D CTLA4 − PD1 + . E CTLA4 + PD1 + . Risk score predicts chemotherapy sensitivity. Cetuximab F, Erlotinib G, Trametinib H, XAV939 I, Docetaxel J, MLN4924 K, OSU-03012 L, YM155 M, Salubrinal N, Vorinostat O

Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us